nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A core outcome set for bronchiectasis in children and adolescents for use in clinical research: an international consensus study
|
Chang, Anne B |
|
|
12 |
1 |
p. 78-88 |
artikel |
2 |
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
|
Bacharier, Leonard B |
|
|
12 |
1 |
p. 45-54 |
artikel |
3 |
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial
|
Ramakrishnan, Sanjay |
|
|
12 |
1 |
p. 67-77 |
artikel |
4 |
Blood eosinophil-guided therapy for COPD exacerbations
|
Comellas, Alejandro P |
|
|
12 |
1 |
p. 9-10 |
artikel |
5 |
Cystic fibrosis: a call for papers for ECFS 2024
|
Grainger, Emma |
|
|
12 |
1 |
p. 13 |
artikel |
6 |
Dupilumab: VOYAGE of discovery leading to a further EXCURSION
|
Paraskakis, Emmanouil |
|
|
12 |
1 |
p. 5-7 |
artikel |
7 |
Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial
|
Dellgren, Göran |
|
|
12 |
1 |
p. 34-44 |
artikel |
8 |
GOLD COPD report: 2024 update
|
Venkatesan, Priya |
|
|
12 |
1 |
p. 15-16 |
artikel |
9 |
Long-term outcomes in hospitalised COVID-19 survivors and future research priorities
|
Routen, Ash |
|
|
12 |
1 |
p. 7-8 |
artikel |
10 |
Minimally invasive thoracic surgery in Sierra Leone and Liberia
|
Gresnigt, Tom M |
|
|
12 |
1 |
p. 19-20 |
artikel |
11 |
Nigeria's battle with diphtheria
|
Makoni, Munyaradzi |
|
|
12 |
1 |
p. 14 |
artikel |
12 |
Once-per-day tacrolimus to reduce chronic lung transplant rejection
|
Combs, Michael P |
|
|
12 |
1 |
p. 3-5 |
artikel |
13 |
Patterns of respiratory infections after COVID-19
|
The Lancet Respiratory Medicine, |
|
|
12 |
1 |
p. 1 |
artikel |
14 |
Primary ciliary dyskinesia treatment: time for a new approach?
|
Maglione, Marco |
|
|
12 |
1 |
p. 2-3 |
artikel |
15 |
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial
|
Ringshausen, Felix C |
|
|
12 |
1 |
p. 21-33 |
artikel |
16 |
The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis
|
Millington, Kerry A |
|
|
12 |
1 |
p. 10-13 |
artikel |
17 |
Updated ESICM guidelines on ARDS
|
Venkatesan, Priya |
|
|
12 |
1 |
p. 16-18 |
artikel |
18 |
3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study
|
Zhang, Hui |
|
|
12 |
1 |
p. 55-66 |
artikel |